Dashboard
Manage Tickers

BMY


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bristol-myers-squibb-presents-data-for-multiple-sclerosis-drug-zeposia-shows-long-term-efficacy
Bristol Myers Squibb Presents Data For Mul...
09/18/2024 13:53:30

Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing mu...

bristol-myers-says-new-data-from-phase-3-daybreak-trial-showed-decreased-rates-of-brain-volume-loss-were-sustained-in-open-label-extension-for-patients-treated-with-zeposia-ozanimod-for-relapsing-forms-of-multiple-sclerosis
Bristol Myers Says New Data From Phase 3 D...
09/18/2024 11:00:51

what-analysts-are-saying-about-bristol-myers-squibb-stock
What Analysts Are Saying About Bristol-Mye...
09/16/2024 21:01:05

cantor-fitzgerald-reiterates-neutral-on-bristol-myers-squibb-maintains-50-price-target
Cantor Fitzgerald Reiterates Neutral on Br...
09/16/2024 15:27:59

Cantor Fitzgerald analyst Olivia Brayer reiterates Bristol-Myers Squibb (NYSE:BMY) with a Neutral and maintains $50 price ta...

Core News & Articles
Immatics Presented The Proof-of-concept Cl...
09/16/2024 09:31:42

Objective response rate (ORR) 29%, confirmed ORR (cORR) 25%, disease control rate (DCR) of 53% and tumor shrinkage rate of 53% ...

reported-sunday-bristol-myers-squibbs-checkmate-067-trial-10-year-follow-up-showed-continued-durable-long-term-survival-benefit-with-opdivo--yervoy-in-advanced-melanoma
Reported Sunday, Bristol Myers Squibb's Ch...
09/16/2024 06:58:04

These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for o...

bernie-sanders-says-if-youre-poor-in-america-youll-live-10-15-years-less-anybody-else-see-a-problem-with-that
Bernie Sanders Says If You're Poor In Amer...
09/10/2024 02:12:36

enliven-therapeutics-leukemia-candidate-could-challenge-pfizer-astrazeneca-in-broader-target-market-analyst
Enliven Therapeutics' Leukemia Candidate C...
09/09/2024 18:05:21

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...

fda-battles-backlog-of-drug-factory-inspections-since-covid-19
FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs
Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

reported-earlier-bristol-myers-squibb-presents-35-year-data-on-camzyos-at-esc-2024
Reported Earlier, Bristol Myers Squibb Pre...
09/03/2024 07:28:31

Bristol Myers Squibb (NYSE:BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-T...

jefferies-maintains-hold-on-bristol-myers-squibb-raises-price-target-to-51
Jefferies Maintains Hold on Bristol-Myers ...
08/28/2024 18:44:01

Jefferies analyst Akash Tewari maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $49 to...

as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-data-disappoints-investors
As Regulators Gear Up To Decide On Bristol...
08/28/2024 15:16:26

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...

kohls-posts-upbeat-q2-earnings-joins-box-waldencast-aerovironment-and-other-big-stocks-moving-higher-on-wednesday
Kohl's Posts Upbeat Q2 Earnings, Joins Box...
08/28/2024 14:17:42

regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna
Regulators Expected To Approve Innovative ...
08/27/2024 19:22:11

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...

market-whales-and-their-recent-bets-on-bmy-options
Market Whales and Their Recent Bets on BMY...
08/27/2024 18:30:48

bristol-myers-squibb-to-present-new-findings-on-camzyos-eliquis-and-milvexian-cardiovascular-treatments-at-esc-congress
Bristol Myers Squibb To Present New Findin...
08/26/2024 11:01:15

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research across its robust cardiovascular portfolio at the ...

cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-limiting-pd-1-drugs-for-stomach-cancer
Cancer Medicines From Merck, Bristol Myers...
08/23/2024 18:10:48

The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors...

bristol-myers-squibb-says-fda-schedules-oncologic-drugs-advisory-committee-meeting-for-september-26-to-discuss-pd-l1-expression-levels-in-gastric-and-esophageal-cancers
Bristol-Myers Squibb Says FDA Schedules On...
08/22/2024 19:08:36

- Reuters 

key-takeaways-from-bristol-myers-squibb-analyst-ratings
Key Takeaways From Bristol-Myers Squibb An...
08/22/2024 15:00:16

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION